We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Viking Therapeutics, Inc. (VKTX - Free Report) . Shares have lost about 23.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Viking Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Wider-Than-Expected Q2 Loss, Nil Sales
Viking reported a second-quarter 2025 loss of 58 cents per share, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 20 cents per share in the year-ago quarter.
Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it has yet to generate revenues.
Quarter in Detail
Research and development (R&D) expenses amounted to $60.2 million, compared with $23.8 million incurred in the year-ago period. This significant increase was primarily driven by higher costs associated with clinical studies and manufacturing for the company’s drug candidates, as well as increased employee-related expenses.
General and administrative expenses amounted to $14.4 million, up 40% year over year, primarily due to higher employee-related expenses.
As of June 30, 2025, Viking had cash, cash equivalents and short-term investments worth $808 million, compared with $852 million as of March 31, 2025.
2025 Guidance
While Viking did not provide hard numbers, it indicated on the conference call that R&D expenses are expected to rise sequentially by approximately 25% to 33% in the third and fourth quarters of 2025 compared with the second quarter.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -47.22% due to these changes.
VGM Scores
At this time, Viking Therapeutics has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Viking Therapeutics has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Viking Therapeutics, Inc. (VKTX - Free Report) . Shares have lost about 23.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Viking Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Wider-Than-Expected Q2 Loss, Nil Sales
Viking reported a second-quarter 2025 loss of 58 cents per share, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 20 cents per share in the year-ago quarter.
Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it has yet to generate revenues.
Quarter in Detail
Research and development (R&D) expenses amounted to $60.2 million, compared with $23.8 million incurred in the year-ago period. This significant increase was primarily driven by higher costs associated with clinical studies and manufacturing for the company’s drug candidates, as well as increased employee-related expenses.
General and administrative expenses amounted to $14.4 million, up 40% year over year, primarily due to higher employee-related expenses.
As of June 30, 2025, Viking had cash, cash equivalents and short-term investments worth $808 million, compared with $852 million as of March 31, 2025.
2025 Guidance
While Viking did not provide hard numbers, it indicated on the conference call that R&D expenses are expected to rise sequentially by approximately 25% to 33% in the third and fourth quarters of 2025 compared with the second quarter.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -47.22% due to these changes.
VGM Scores
At this time, Viking Therapeutics has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Viking Therapeutics has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.